Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3146264 | 0.93 | DYRK1A (0.43) | RAB9AMAPTGAAPOLBSMN1; SMN2 | |
| SCHEMBL3121109 | 0.92 | SCN9A (0.45) | RAB9AMAPTGAAPOLBSMN1; SMN2 | |
| SCHEMBL13414023 | 0.92 | SCN9A (0.44) | RAB9AMAPTGAAPOLBSMN1; SMN2 | |
| SCHEMBL3140989 | 0.91 | AGPAT2 (0.45) | RAB9AMAPTGAAPOLBSMN1; SMN2 | |
| SCHEMBL3117071 | 0.91 | MAPT (0.46) | RAB9AMAPTGAAPOLBSMN1; SMN2 | |
| SCHEMBL3119522 | 0.90 | ROCK1 (0.45) | IKBKBAGPAT2KCNH2SCN9AROCK1 | |
| SCHEMBL13414016 | 0.90 | AGPAT2 (0.42) | KMT2AMEN1IKBKBAGPAT2KCNH2 | |
| SCHEMBL3117362 | 0.90 | AGPAT2 (0.56) | IKBKBAGPAT2KCNH2SCN9ASCN5A | |
| SCHEMBL1644554 | 0.90 | AGPAT2 (0.55) | MAPTPOLBSMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13413991 | 0.90 | IKBKB (0.43) | RAB9AMAPTGAAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-03-25 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7678804-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-03-16 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582645-B2 | Pyrimidine derivatives for treatment of hyperproliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075967-A1 | PYRIMIDINE DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE DISORDERS | TYMP, DPYD, CCNA2 | RAB9A 2850/4885MAPT 4585/4885GAA 1507/4885 |
| US-20070117817-A1 | 4-{3-[(2-Amino-6-phenylpyrimidin-4-yl)amino]phenoxy}-N-methylpyridine-2-carboxamide;anticarcinogenic agents; breast cancer; antitumor agents; respiratory system disorders; urogenital disorders; gastrointestinal disorders; skin disorders; glandular disorders; lymphomas; leukemia; cytolysis | CCNA2, MALT1, TPD52L2 | RAB9A 3476/4885MAPT 4840/4885GAA 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.